How good is anticoagulation control in non-valvar atrial fibrillation? Observations on the elderly, ethnicity, patient perceptions, and understanding of AF thromboprophylaxis
- Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
- Correspondence to:
Professor Gregory Y H Lip
Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK; g.y.h.lipbham.ac.uk
Abstract
There continues to be a wide variation of opinion among UK consultants regarding the best treatment strategies for ensuring effective thromboprophylaxis of atrial fibrillation
Footnotes
-
Competing interests: GYHL is Clinical Adviser to the Guideline Development Group developing the NICE Guidelines on Atrial Fibrillation. In addition, he has received research funding and honoraria for meetings, educational symposia and advisory boards from various pharmaceutical companies involved in antithrombotic agents and other drugs used in the management of atrial fibrillation.
